Lithium distribution in mania: Plasma and red blood cell lithium, clinical state, and monoamine metabolites during lithium treatment

Alan C. Swann, Nancy Berman, Alan Frazer, Stephen H. Koslow, Steven Secunda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We examined red blood cell (RBC) and plasma lithium concentrations and RBC/plasma lithium ratios in 14 manic patients during lithium treatment as part of the National Institute of Mental Health's Collaborative Program on the Psychobiology of Depression, Biological Studies. All of the lithium measures increased during treament, especially RBC lithium. There were positive correlations between the RBC lithium concentration and the RBC/plasma lithium ratio and their maximal values in a single-dose pharmacokinetic experiment before treatment. After 5 and 16 days of treatment, patients with good subsequent outcome had higher RBC/plasma lithium ratios than did patients with poor outcome. Early in treatment, there was a negative correlation between lithium concentrations and severity of mania. During treatment, there was a negative correlation between RBC lithium and urinary MHPG excretion. There was a positive correlation between RBC or plasma lithium during the first few days of treatment and subsequent reduction in norepinephrine excertion during treatment. At 3 weeks, there were negative correlations between reductions in catecholamine measures and lithium concentrations. These data suggest that there are changes in the sensitivity of behavior and catecholamine function to lithium during treatment. RBC concentrations of lithium appear to be a potentially useful indicator of its behavioral and neurochemical effects.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalPsychiatry Research
Volume20
Issue number1
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Bipolar Disorder
Lithium
Erythrocytes
Therapeutics
Catecholamines
Methoxyhydroxyphenylglycol
National Institute of Mental Health (U.S.)
Norepinephrine
Pharmacokinetics
Depression

Keywords

  • catecholamines
  • lithium distribution
  • lithium treatment
  • Mania

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Lithium distribution in mania : Plasma and red blood cell lithium, clinical state, and monoamine metabolites during lithium treatment. / Swann, Alan C.; Berman, Nancy; Frazer, Alan; Koslow, Stephen H.; Secunda, Steven.

In: Psychiatry Research, Vol. 20, No. 1, 1987, p. 1-12.

Research output: Contribution to journalArticle

Swann, Alan C. ; Berman, Nancy ; Frazer, Alan ; Koslow, Stephen H. ; Secunda, Steven. / Lithium distribution in mania : Plasma and red blood cell lithium, clinical state, and monoamine metabolites during lithium treatment. In: Psychiatry Research. 1987 ; Vol. 20, No. 1. pp. 1-12.
@article{c41a43654c2e43fa9533b6ddd6b915b1,
title = "Lithium distribution in mania: Plasma and red blood cell lithium, clinical state, and monoamine metabolites during lithium treatment",
abstract = "We examined red blood cell (RBC) and plasma lithium concentrations and RBC/plasma lithium ratios in 14 manic patients during lithium treatment as part of the National Institute of Mental Health's Collaborative Program on the Psychobiology of Depression, Biological Studies. All of the lithium measures increased during treament, especially RBC lithium. There were positive correlations between the RBC lithium concentration and the RBC/plasma lithium ratio and their maximal values in a single-dose pharmacokinetic experiment before treatment. After 5 and 16 days of treatment, patients with good subsequent outcome had higher RBC/plasma lithium ratios than did patients with poor outcome. Early in treatment, there was a negative correlation between lithium concentrations and severity of mania. During treatment, there was a negative correlation between RBC lithium and urinary MHPG excretion. There was a positive correlation between RBC or plasma lithium during the first few days of treatment and subsequent reduction in norepinephrine excertion during treatment. At 3 weeks, there were negative correlations between reductions in catecholamine measures and lithium concentrations. These data suggest that there are changes in the sensitivity of behavior and catecholamine function to lithium during treatment. RBC concentrations of lithium appear to be a potentially useful indicator of its behavioral and neurochemical effects.",
keywords = "catecholamines, lithium distribution, lithium treatment, Mania",
author = "Swann, {Alan C.} and Nancy Berman and Alan Frazer and Koslow, {Stephen H.} and Steven Secunda",
year = "1987",
doi = "10.1016/0165-1781(87)90118-1",
language = "English (US)",
volume = "20",
pages = "1--12",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Lithium distribution in mania

T2 - Plasma and red blood cell lithium, clinical state, and monoamine metabolites during lithium treatment

AU - Swann, Alan C.

AU - Berman, Nancy

AU - Frazer, Alan

AU - Koslow, Stephen H.

AU - Secunda, Steven

PY - 1987

Y1 - 1987

N2 - We examined red blood cell (RBC) and plasma lithium concentrations and RBC/plasma lithium ratios in 14 manic patients during lithium treatment as part of the National Institute of Mental Health's Collaborative Program on the Psychobiology of Depression, Biological Studies. All of the lithium measures increased during treament, especially RBC lithium. There were positive correlations between the RBC lithium concentration and the RBC/plasma lithium ratio and their maximal values in a single-dose pharmacokinetic experiment before treatment. After 5 and 16 days of treatment, patients with good subsequent outcome had higher RBC/plasma lithium ratios than did patients with poor outcome. Early in treatment, there was a negative correlation between lithium concentrations and severity of mania. During treatment, there was a negative correlation between RBC lithium and urinary MHPG excretion. There was a positive correlation between RBC or plasma lithium during the first few days of treatment and subsequent reduction in norepinephrine excertion during treatment. At 3 weeks, there were negative correlations between reductions in catecholamine measures and lithium concentrations. These data suggest that there are changes in the sensitivity of behavior and catecholamine function to lithium during treatment. RBC concentrations of lithium appear to be a potentially useful indicator of its behavioral and neurochemical effects.

AB - We examined red blood cell (RBC) and plasma lithium concentrations and RBC/plasma lithium ratios in 14 manic patients during lithium treatment as part of the National Institute of Mental Health's Collaborative Program on the Psychobiology of Depression, Biological Studies. All of the lithium measures increased during treament, especially RBC lithium. There were positive correlations between the RBC lithium concentration and the RBC/plasma lithium ratio and their maximal values in a single-dose pharmacokinetic experiment before treatment. After 5 and 16 days of treatment, patients with good subsequent outcome had higher RBC/plasma lithium ratios than did patients with poor outcome. Early in treatment, there was a negative correlation between lithium concentrations and severity of mania. During treatment, there was a negative correlation between RBC lithium and urinary MHPG excretion. There was a positive correlation between RBC or plasma lithium during the first few days of treatment and subsequent reduction in norepinephrine excertion during treatment. At 3 weeks, there were negative correlations between reductions in catecholamine measures and lithium concentrations. These data suggest that there are changes in the sensitivity of behavior and catecholamine function to lithium during treatment. RBC concentrations of lithium appear to be a potentially useful indicator of its behavioral and neurochemical effects.

KW - catecholamines

KW - lithium distribution

KW - lithium treatment

KW - Mania

UR - http://www.scopus.com/inward/record.url?scp=0023095736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023095736&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(87)90118-1

DO - 10.1016/0165-1781(87)90118-1

M3 - Article

C2 - 2882535

AN - SCOPUS:0023095736

VL - 20

SP - 1

EP - 12

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -